Viral Vector Contract Development and Manufacturing Organization (CDMO) Global Market Report 2025

The viral vector contract development and manufacturing organization (CDMO) market size has grown rapidly in recent years. It will grow from $1.27 billion in 2024 to $1.47 billion in 2025 at a compound annual growth rate (CAGR) of 15.8%. The growth during the historic period can be attributed to the increasing number of gene therapy and cell therapy clinical programs, rising healthcare expenditure, early regulatory approvals supporting viral vector therapeutics, growing investments in specialized facilities, and dependence on plasmid DNA supply.

The viral vector contract development and manufacturing organization (CDMO) market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2029 at a compound annual growth rate (CAGR) of 15.4%. The growth during the forecast period can be attributed to the commercialization of more gene therapies for both common and rare diseases, rapid expansion of outsourced capacity and CDMO investments, regulatory harmonization, increasing demand for on-demand, personalized, and autologous manufacturing, and the rising prevalence of chronic diseases. Key trends in the forecast period include consolidation and vertical integration among large CDMOs and biopharma companies, regional capacity expansion, ongoing focus on cost reduction through process optimization and economies of scale, diversification into plasmid DNA, non-viral platforms, and fill-finish services, and adoption of digital or AI-enabled monitoring and quality control.

The growing investment in gene therapy research is expected to drive the growth of the viral vector contract development and manufacturing organization (CDMO) market in the coming years. Gene therapy research focuses on methods to modify or regulate genes in human cells to correct genetic disorders or treat various diseases. Investment in this area is increasing due to the potential of gene therapies to provide long-term or permanent cures for previously untreatable genetic conditions, attracting strong interest from healthcare innovators and investors. Viral vector CDMOs support gene therapy research by providing specialized expertise and advanced production facilities to manufacture high-quality viral vectors, which are essential for the safe and effective delivery of therapeutic genes. For example, in July 2025, the UK’s Office for Life Sciences reported a government commitment of up to $800 million (£600 million) to develop a secure, AI-compatible health data platform integrating genomic, diagnostic, and clinical information at a population level, aiming to transform NHS and global healthcare data into a hub for research trials and AI investment. Therefore, rising investment in gene therapy research is fueling the growth of the viral vector CDMO market.

Leading companies in the viral vector CDMO market are advancing viral vector manufacturing solutions to support scalable and efficient gene therapy production. AAV manufacturing solutions, for instance, involve systems and techniques developed to efficiently produce safe and effective adeno-associated virus vectors for gene therapy. In August 2025, ProBio, a US-based CDMO, launched cGMP AAV manufacturing services at its 128,000 sq. ft. facility in Hopewell, New Jersey. This expansion meets the growing demand for high-quality viral vector production and demonstrates ProBio’s commitment to supporting innovative gene therapies. The Hopewell facility provides fully integrated services including GMP plasmid DNA production, AAV vector manufacturing, and final drug product formulation with aseptic fill-finish, all in one location. This integrated approach improves coordination, reduces process handoffs, and accelerates timelines across the drug development lifecycle.

In May 2023, Siegfried, a Switzerland-based life sciences company, acquired a 95% stake in DINAMIQS for an undisclosed amount. This acquisition allows Siegfried to scale DINAMIQS’ capabilities to commercial levels, positioning it as a leading biotech CDMO for cell and gene therapies. The move strengthens Siegfried’s presence in the biologics sector and is expected to create significant mid- to long-term growth opportunities in this rapidly evolving market. DINAMIQS provides comprehensive contract development and manufacturing services for viral vectors.

Major players in the viral vector contract development and manufacturing organization (CDMO) market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, WuXi AppTec, Samsung Biologics Co. Ltd., FUJIFILM Biotechnologies, Oxford Biomedica Plc, Hillgene, Takara Bio Inc., SkyPharma Production SAS, GeneScript ProBio, Obio Technology Corp. Ltd., VectorBuilder, Charles River Laboratories Pvt. Ltd., Creative Biogene, Esco Aster Pte. Ltd., Genesail Biotech Co. Ltd., CEVEC Pharmaceuticals, Cell and Gene Therapy Catapult, CoJourney, and Applied Biological Laboratories Inc.

North America was the largest region in the viral vector contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in viral vector contract development and manufacturing organization (CDMO) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The viral vector contract development and manufacturing organization (CDMO) market research report is one of a series of new reports that provides viral vector contract development and manufacturing organization (CDMO) market statistics, including viral vector contract development and manufacturing organization (CDMO) industry global market size, regional shares, competitors with a viral vector contract development and manufacturing organization (CDMO) market share, detailed viral vector contract development and manufacturing organization (CDMO) market segments, market trends and opportunities, and any further data you may need to thrive in the viral vector contract development and manufacturing organization (CDMO) industry. This viral vector contract development and manufacturing organization (CDMO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A viral vector contract development and manufacturing organization (CDMO) is a specialized company that focuses on the development and large-scale production of viral vectors used in advanced biological therapies. It provides the necessary technical expertise, infrastructure, and regulatory compliance to support the complete viral vector manufacturing process.

The primary services offered by viral vector CDMOs include process development, manufacturing, analytical testing, fill-finish, and more. Process development in pharmaceutical manufacturing involves designing and optimizing production processes to ensure efficient, scalable, and reproducible outcomes. The different vector types include adenoviral vectors, lentiviral vectors, adeno-associated viral vectors, retroviral vectors, and others, with workflows covering upstream and downstream manufacturing. These services are applied in gene therapy, vaccines, cell therapy, and other areas, and the key end-users include pharmaceutical and biotechnology companies, academic and research institutes, and additional organizations.

The countries covered in the viral vector contract development and manufacturing organization (CDMO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The viral vector contract development and manufacturing organization (CDMO) market consists of revenues earned by entities by providing services such as cell line development, preclinical material production, quality control testing, and supply chain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral vector contract development and manufacturing organization (CDMO) market also includes sales of helper plasmids, packaging cell lines, producer cell banks, and purified viral vector components. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.